Florida Cancer Specialists: Bringing Telemedicine to Oncology Practice in COVID-19

Experts from Florida Cancer Specialists cover how the COVID-19 pandemic is transforming telemedicine in oncology by addressing billing, operations, training and provider perspectives in this webinar presented on Monday, April 20, 2020.

Related Videos

Related Content

Advertisement

April 18th 2025

Consensus Guidelines Aim to Optimize DMD Gene Therapy Delivery

Rose McNulty

Multidisciplinary coordination across prescribing teams, nursing, laboratory medicine, finance, and infusion centers is crucial for gene therapy delivery in Duchenne muscular dystrophy (DMD).

April 15th 2025

Personalized Care Key as Tirzepatide Use Expands Rapidly

Maggie L. Shaw John W. Ostrominski, MD

Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.

April 18th 2025

"The Barriers Are Real": Antoine Keller, MD, on Geography and Cardiovascular Health

Kyle Munz Antoine Keller, MD, FACC, FACS

Health care disparities are often driven by where patients live, explained Antoine Keller, MD, as he discussed the complex, systematic hurdles that influence the health of rural communities.

April 10th 2025

Managed Care Cast Presents: Unlocking the Potential of CGM Technology

Laura Joszt, MA

A group of experts discusses the use of continuous glucose monitoring (CGM) technology in diabetes and its transformative potential in managing the disease.

April 18th 2025

Understanding How Fitness Affects Digestive Diseases

Skylar Jeremias

Exercise is a powerful modulator of gut health in patients with gastrointestinal (GI) conditions, as moderate activity can ease gut inflammation, reduce colorectal cancer risk, and relieve constipation, while intense workouts may backfire, causing reflux, GI bleeding, or gut barrier disruption.

April 18th 2025

FDA Greenlights Dupilumab for Chronic Spontaneous Urticaria, Marking First Approval in a Decade

Cameron Santoro

Marking the first approval in over a decade for this challenging condition, the FDA has approved dupilumab (Dupixent) to treat chronic spontaneous urticaria in patients 12 years and older whose hives and itching remain uncontrolled by antihistamines.

Related Content

Advertisement

April 18th 2025

Consensus Guidelines Aim to Optimize DMD Gene Therapy Delivery

Rose McNulty

Multidisciplinary coordination across prescribing teams, nursing, laboratory medicine, finance, and infusion centers is crucial for gene therapy delivery in Duchenne muscular dystrophy (DMD).

April 15th 2025

Personalized Care Key as Tirzepatide Use Expands Rapidly

Maggie L. Shaw John W. Ostrominski, MD

Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.

April 18th 2025

"The Barriers Are Real": Antoine Keller, MD, on Geography and Cardiovascular Health

Kyle Munz Antoine Keller, MD, FACC, FACS

Health care disparities are often driven by where patients live, explained Antoine Keller, MD, as he discussed the complex, systematic hurdles that influence the health of rural communities.

April 10th 2025

Managed Care Cast Presents: Unlocking the Potential of CGM Technology

Laura Joszt, MA

A group of experts discusses the use of continuous glucose monitoring (CGM) technology in diabetes and its transformative potential in managing the disease.

April 18th 2025

Understanding How Fitness Affects Digestive Diseases

Skylar Jeremias

Exercise is a powerful modulator of gut health in patients with gastrointestinal (GI) conditions, as moderate activity can ease gut inflammation, reduce colorectal cancer risk, and relieve constipation, while intense workouts may backfire, causing reflux, GI bleeding, or gut barrier disruption.

April 18th 2025

FDA Greenlights Dupilumab for Chronic Spontaneous Urticaria, Marking First Approval in a Decade

Cameron Santoro

Marking the first approval in over a decade for this challenging condition, the FDA has approved dupilumab (Dupixent) to treat chronic spontaneous urticaria in patients 12 years and older whose hives and itching remain uncontrolled by antihistamines.